Stay updated with breaking news from Hite Count. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Compared with a single dose, more patients in the split-dose group had improved disease activity at 16 weeks, and fewer needed additional DMARDs, but the effect was not found at 24 weeks.
The approval allows for continuous immunotherapy treatment around surgery for resectable non-small cell lung cancer.
The agency approved the tyrosine kinase inhibitor for pediatric patients with chronic phase Ph+ chronic myelogenous leukemia that is newly diagnosed or resistant or intolerant to prior therapy.
Over the last few years, physicians have experimented with taking patients with chronic myeloid leukemia (CML) off their drugs entirely, and the results are promising.
Protein changes in peripheral blood samples in the first 24 hours after starting chemotherapy could predict which patients with acute myeloid leukemia respond.